HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy : an analysis of real-world clinical practice data in Japan

Creative Commons License

Files in This Item:
hyy094.pdf253.67 kBPDFView/Open
hyy094_supplemently_table1.docSupplementary data93 kBMicrosoft WordView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/72012

Title: Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy : an analysis of real-world clinical practice data in Japan
Authors: Matsumoto, Ryuji Browse this author
Abe, Takashige Browse this author →KAKEN DB
Ishizaki, Junji Browse this author
Kikuchi, Hiroshi Browse this author
Harabayashi, Toru Browse this author
Minami, Keita Browse this author
Sazawa, Ataru Browse this author →KAKEN DB
Mochizuki, Tango Browse this author
Akino, Tomoshige Browse this author
Murakumo, Masashi Browse this author
Osawa, Takahiro Browse this author
Maruyama, Satoru Browse this author →KAKEN DB
Murai, Sachiyo Browse this author
Shinohara, Nobuo Browse this author →KAKEN DB
Keywords: urothelial carcinoma
chemotherapy
second-line
metastatic
Issue Date: Aug-2018
Publisher: Oxford University Press
Journal Title: Japanese journal of clinical oncology
Volume: 48
Issue: 8
Start Page: 771
End Page: 776
Publisher DOI: 10.1093/jjco/hyy094
Abstract: Objectives: The objective of the present study was to investigate the survival outcome and prognostic factors of metastatic urothelial carcinoma patients treated with second-line systemic chemotherapy in real-world clinical practice. Methods: Overall, 114 patients with metastatic urothelial carcinoma undergoing second-line systemic chemotherapy were included in this retrospective analysis. The dominant second-line chemotherapy was a paclitaxel-based combination regimen (60%, 68/114). We assessed the progression-free survival and overall survival times using the Kaplan-Meier method. The Cox proportional hazards model was applied to identify the factors affecting overall survival. Results: The median progression-free survival and overall survival times were 4 and 9 months, respectively. In the multivariate analysis, an Eastern Cooperative Oncology Group performance status score greater than 0 at presentation, C-reactive protein level ≧1 mg/dl and poor response to prior chemotherapy were adverse prognostic indicators. Patients with 0, 1, 2 and 3 of those risk factors had a median overall survival of 17, 12, 7 and 3 months, respectively. Conclusions: The Eastern Cooperative Oncology Group performance status at presentation, C-reactive protein level and response to prior chemotherapy were prognostic factors for metastatic urothelial carcinoma patients undergoing second-line chemotherapy. In the future, this information might help guide the choice of salvage treatment, such as second-line chemotherapy or immune checkpoint inhibitors, after the failure of first-line chemotherapy.
Rights: http://creativecommons.org/licenses/by-nc/4.0/
Type: article
URI: http://hdl.handle.net/2115/72012
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 安部 崇重

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University